Disease-free survival in Philadelphia chromosome-positive ALL (Ph þ ALL) is very poor, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently considered the only procedure with curative potential. To identify factors affecting transplant outcome, we analyzed the data from 197 Ph þ ALL patients aged 16 years or older who had undergone allo-HSCT. The 5-year survival rates were 34% for patients in first complete remission (CR), 21% for those in second or subsequent CR, and 9% for those with active disease (Po0.0001). Multivariate analysis showed four pre-transplant factors as significantly associated with better survival: younger age, CR at the time of transplantation, conditioning with total body irradiation, and HLA-identical sibling donor (Po0.0001, Po0.0001, P ¼ 0.0301, P ¼ 0.0412, respectively). Severe acute GVHD increased the risk of treatment-related mortality (TRM) without diminishing the risk of relapse, whereas chronic GVHD reduced the risk of relapse without increasing the risk of TRM. Thus, patients who developed extensive chronic GVHD had better survivals (P ¼ 0.0217), and those who developed grade III-IV acute GVHD had worse survivals (P ¼ 0.0023) than did the others.
Philadelphia chromosome (Ph), a t(9;22) reciprocal translocation, is the most unfavorable prognostic marker for ALL, and has been detected in up to 30% of adult patients with ALL. Although conventional chemotherapy results in 50-80% of patients attaining complete remission (CR), long-term survival can rarely be achieved because of the extremely high relapse rate. [1] [2] [3] [4] [5] [6] [7] We and other investigators have recently reported promising results using chemotherapy in combination with imatinib for Ph-positive ALL (Ph þ ALL), 8, 9 but longer follow-up is needed to determine whether imatinib-containing therapy by itself can be curative. At present it is thought that allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option for this disease. Several articles have dealt with the outcome for Ph þ ALL patients undergoing allo-HSCT, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] but more detailed information is needed on a larger number of subjects. We therefore undertook a retrospective study involving 197 Ph þ ALL patients, using the registry data of the Japan Society of Hematopoietic Cell Transplantation (JSHCT).
Patients and methods

Patients
A nationwide survey on HSCT has been conducted in Japan by the JSHCT. Registration is voluntary, and the number of transplants reported is around 2500 per year. Patients were eligible if they had been diagnosed as Ph þ ALL, were aged 16 years or older at the time of transplantation, and had undergone allo-HSCT between January 1991 and December 2001. None of them had been treated with imatinib mesylate. Those who had undergone a second or subsequent transplant, a nonmyeloablative stem cell transplant or a cord blood transplant were excluded. Sibling pairs who were matched by serology for HLA-A, -B, and -DR loci were considered to be HLAidentical. DNA typing for HLA-DRB1 alleles was performed for most unrelated pairs, and that for HLA-A and -B alleles was performed in more recent cases. For unrelated pairs, HLA compatibility was estimated on the basis of available data reported to the registry, thus considering some mismatched pairs as matched. 23 All donors except for HLA-identical siblings were classified as alternative donors. Information on surviving patients was updated annually. This study was approved by the Committee for Nationwide Survey Data Management of the JSHCT.
Statistical analysis
The primary objective of this study was to identify pretransplant factors associated with overall survival (OS) for patients with Ph þ ALL. The secondary objective was to assess the effect of GVHD on outcome. OS was defined as the time from the day of transplantation to death or last follow-up, and leukemia-free survival (LFS) as the time from the day of transplantation to relapse, death, or last follow-up. Acute and chronic GVHD were evaluated according to the standard criteria. 24, 25 Those who died before engraftment were excluded from the analysis of acute GVHD, and those who survived 100 days post transplant without relapse were included in the analysis of chronic GVHD. The Cox proportional hazards regression model was employed to assess the effect of pre-transplant factors. Factors with P-values of less than 0.10 for univariate analysis were included in the subsequent multivariate Cox model. Hazard ratio (HR) was calculated in conjunction with a 95% confidence interval (CI). To evaluate the independent effect of GVHD on outcome, the presence or absence of grade II-IV acute GVHD, grade III-IV acute GVHD, any form of chronic GVHD, or extensive chronic GVHD was included separately in an additional Cox model consisting of significant pre-transplant factors. Kaplan-Meier analyses were performed to estimate the probability of OS and LFS. Differences between the curves were compared by means of the logrank test. StatView 5.0 (SAS Institute Inc., Cary, NC, USA) was used for all statistical analyses.
Results
Patient characteristics
Baseline characteristics of the 197 subjects eligible for analysis are presented in 
Pre-transplant prognostic factors
The probability of OS at 5 years for the entire population was 22%. Figure 1 shows Kaplan-Meier survival estimates according to disease status at the time of transplantation. The 5-year survival rates were 34% for patients in first CR, 21% for patients in second or subsequent CR, and 9% for patients with active disease (Po0.0001 among the three groups). The eight pre-transplant variables subjected to risk factor analysis were age, sex, year of transplantation, graft source (bone marrow or peripheral blood), donor type (HLA-identical sibling or alternative donor), disease status (CR or non-CR), conditioning (TBI regimen or non-TBI regimen), and GVHD prophylaxis (CsA-based or FK506-based regimen). The results of univariate and multivariate analyses are summarized in Table 2 . Significantly favorable factors identified in the multivariate analysis were younger age (Po0.0001), CR at the time of transplantation 
Influence of GVHD on survival
We then investigated whether development of GVHD had a significant influence on survival. The effects of four types of GVHD (grade II-IV acute GVHD, grade III-IV acute GVHD, any form of chronic GVHD, and extensive chronic GVHD) were examined. Acute GVHD was evaluable for 166 patients, 63 of whom had developed grade II-IV and 23 grade III-IV. Chronic GVHD could be evaluated for 115 patients, 28 of whom had developed the limited form and 34 the extensive form. Figure 3 compares survival curves for patients with or without each type of GVHD. As described in the 'Patients and methods' section, the presence or absence of each type of GVHD was included separately in the Cox model containing the four significant pre-transplant risk factors. The survival rate was almost identical for patients with and without grade II-IV acute GVHD (HR, 1.00; 95% CI, 0.68-1.46; P ¼ 0.9791; logrank, P ¼ 0.3926). In contrast, grade III-IV acute GVHD had a significant impact on survival, with patients in this category having a chance of survival that was 1.7 times lower than for those not in this category (HR, 0.58; 95% CI, 0.34-0.98; P ¼ 0.0430; log-rank, P ¼ 0.0023). For patients developing any form of chronic GVHD, there was a nonsignificant increase in survival rate compared with those who did not (HR, 1.40; 95% CI, 0.85-2.32; The 5-year survival rates were estimated to be 34% for patients in first complete remission (CR), 21% for patients in second or subsequent CR, and 9% for patients with active disease (Po0.0001 among the three groups). 
P=0.0230
non-TBI (n =31) Figure 2 Probabilities of survival for patients conditioned with or without TBI conditioning. The 5-year survival rates were estimated to be 25% for patients whose conditioning contained TBI, and 8% for those whose did not (P ¼ 0.0230).
Allogeneic HSCT for Ph-positive ALL M Yanada et al P ¼ 0.1877; log-rank, P ¼ 0.1065). With extensive chronic GVHD, the survival advantage was statistically significant (HR, 2.10; 95% CI, 1.13-3.88; P ¼ 0.0179; log-rank, P ¼ 0.0217). The 5-year OS was estimated to be 51% for those with extensive chronic GVHD and 29% for those without. Chronic GVHD was associated with a lower risk of relapse without increasing the risk of TRM, whereas severe acute GVHD was associated with a higher risk of TRM without diminishing the risk of relapse (Table 3) . When grade II acute GVHD was compared with grade 0-1, no significant effects were noted in terms of OS, relapse, or TRM (data not shown). Figure 4 shows LFS according to the severity of chronic GVHD. The beneficial effect was restricted to the extensive form, and no difference was found between patients with the limited form and those without chronic GVHD.
Discussion
Several prospective studies have demonstrated the superiority of allo-HSCT over chemotherapy and autologous transplantation for high-risk ALL. 18, [26] [27] [28] [29] With Ph þ ALL in particular, allo-HSCT is currently considered the only curative approach. It is therefore quite important to clarify what are the essential elements for the success of allo-HSCT for this subset. By analyzing the data of 197 patients with Ph þ ALL, we identified four pretransplant factors associated with survival, as well as a significant effect of GVHD on outcome. Not surprisingly, advanced age, active disease at the time of transplantation, and an alternative donor impaired survival. All of them were associated with higher risk of TRM, and active disease also with higher risk of relapse. Additionally, we found that TBI conditioning produced a significant survival advantage. Although patients who received a TBI-containing regimen tended to be younger than those who did not (median age, 37 vs 42 years; P ¼ 0.0222), the correlation remained significant after adjusting for age. This finding may be explained by the fact that TBI conditioning tended to reduce the risk of relapse, although without reaching statistical significance (HR, 1.67; 95% CI, 0.90-3.11; P ¼ 0.1050). Taking into account the finding of a previous study that TBI conditioning correlates with a higher risk of TRM and shorter OS for patients aged 50 years or older, 30 it seems advisable to use TBI conditioning for Ph þ ALL patients younger than 50 years. Furthermore, our study demonstrated that GVHD has a strong effect on outcome. Severe acute GVHD predisposed patients to an increased risk of TRM without reducing the risk of relapse, while chronic GVHD conferred a protective effect against relapse without increasing the risk of TRM. The presence of GVL effect in ALL has been shown, 31 although, its role does not seem as prominent as that in other diseases such as chronic myeloid leukemia. Allo-HSCT with reduced-intensity conditioning (RIST) has been developed recently, but data for ALL patients are limited. 32, 33 Our findings confirmed the clinically significant GVL effect for this disease, thus providing a rationale for investigating RIST for Ph þ ALL patients who are poor candidates for conventional transplantation. On the other hand, the observation that active disease at the time of transplant strongly impaired outcome might indicate that tumor burden, that is cytotoxic effect, also plays a critical part. The role of RIST for this disease should be further investigated. With respect to the beneficial role of chronic GVHD, our results are in accordance with several studies focusing on Ph þ ALL, 20, 21 but contrast with the previous report from the JSHCT, where no significant effect was shown for ALL cases. 34 It can be speculated that this discrepancy reflects the difference between Ph þ ALL and non-Ph ALL. The importance of the GVL effect may be greater for Ph þ ALL, the subset most resistant to chemotherapy, and a potent GVL effect may be necessary for preventing disease recurrence.
From these findings, the best results are to be expected if Ph þ ALL patients are transplanted in CR with a TBI-containing regimen. Extensive chronic GVHD has a beneficial effect on survival, although it should be noted that the use of imatinib before and after allo-HSCT may possibly change the situation. effect was restricted to the extensive form (Extensive), and no difference was found between patients with the limited form (Limited) and those without chronic GVHD (None).
